Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

LadRx Corp LADX

Healthcare Biotechnology
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.


OTCQB:LADX - Post by User

LadRx Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by samantha231on Mar 27, 2014 2:24pm
434 Views
Post# 22377404

CYTR and ICLD have same lies from blog seekingalpha

CYTR and ICLD have same lies from blog seekingalphaJust to advise you that CYTR and ICLD have exactly the same lawsuits being filed against them and all stemming from the blogger seekingalpha.com.
Exactly the same law firms are involved in both companies and for the exact same reasons in both cases 'that the prices were inflated by the Dream Team'. Both companies have explanations that are carbon copies of each other with same legal coucil for both..
These tactics have driven down both stocks and someone is definitely cashing in.  
I will definitely be looking into filing complaints against seekingalpha.com and their associates for possibly their own security fraud. Their claims against two companies is the key. Perhaps when investigated, shareholders shld be in litigation in seeking damages against the blogger.

I am still invested in CYTR. good luck.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities